Please assess the completion status of the following clinical trial:

Trial Title: The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Major inclusion criteria~* had a histologically proven adenocarcinoma of the gastroesophageal junction, or stomach that was locally advanced (inoperable) or metastatic~* measurable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST)1.1~* an Eastern Cooperative Oncology Group performance status of 0 to 2~* adequate renal, hepatic, and hematologic function~Major exclusion criteria~* previous chemotherapy or radiotherapy (unless in the adjuvant setting)~* uncontrolled cardiac disease, or other clinically significant, uncontrolled coexisting illness or previous or concurrent cancer~* accumulated dose of Epirubicin exceeds 300mg/m2~* HER2 positive and willing to use trastuzumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- XELOX (Type: EXPERIMENTAL): oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；
- EOX (Type: ACTIVE_COMPARATOR): Epirubicin 50mg/m2 d1； oxaliplatin 130mg/m2 d1； capecitabine 1000mg/m2 Bid po，d1-14；

Based on this trial design, predict the completion outcome and termination type (if applicable).